Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

GMED stock hub

Globus Medical, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GMEDis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

10.6B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

GMED

In the news

Latest news · GMED

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E16.3

P25 12.3P50 18.4P75 33.1

Trailing P/E18.2

P25 14.9P50 23.2P75 38.5

ROE13.3

P25 -105.6P50 -46.5P75 -3.1

ROIC14.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GMED market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

265

Groups with data

Currency

USD

Showing 265 of 265 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001237831
Company name	Globus Medical, Inc.
Country	United States
Country code	US
Cusip	379577208
Employees	6,000
Employees Change	700%
Employees Change Percent	13.21
Enterprise value	$9.9B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Medical Devices
IPO Date	2012-08-03
Isin	US3795772082
Last refreshed	2026-05-10
Market cap	$10.6B
Market cap category	Large-Cap
Price	$77.95
Price currency	USD
Rev Per Employee	516,777.33x
Sector	Healthcare
Sic	3841
Symbol	GMED
Website	https://www.globusmedical.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.54%
EV Earnings	16.87x
EV Sales Forward	2.99x
EV/EBIT	14.91x
EV/EBITDA	10.47x
EV/FCF	16.22x
EV/Sales	3.19x
FCF yield	5.77%
Forward P/E	16.33x
P/B ratio	2.23x
P/E ratio	18.17x
P/S ratio	3.41x
PE Ratio10 Y	46.3x
PE Ratio3 Y	68.42x
PE Ratio5 Y	57.44x
PEG ratio	1.6x
PS Forward	3.2x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	21.41%
EBITDA Margin	30.48%
FCF margin	19.68%
Gross margin	68.49%
Gross Profit	$2.1B
Gross Profit Growth	26.16%
Gross Profit Growth Q	30.54%
Gross Profit Growth3 Y	38.83%
Gross Profit Growth5 Y	28.67%
Net Income	$586.7M
Net Income Growth	216.18%
Net Income Growth Q	64.72%
Net Income Growth Quarters	7%
Net Income Growth Years	1%
Net Income Growth3 Y	42.86%
Net Income Growth5 Y	36.98%
Pretax Margin	21.24%
Profit Margin	18.92%
Profit Per Employee	$97,785
Profitable Years	17
ROA	8.18
Roa5y	6.25
ROCE	13.39
ROE	13.3
Roe5y	7.76
ROIC	14.16
Roic5y	11.55

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.04%
Cagr1y	9.01%
Cagr3y	10.07%
Cagr5y	1.24%
EPS Growth	221.1
EPS Growth Q	66.67
EPS Growth Quarters	7
EPS Growth Years	1
EPS Growth3 Y	29.79
EPS Growth5 Y	28.96
FCF Growth	16.79%
FCF Growth Q	15.26%
FCF Growth3 Y	73.42%
FCF Growth5 Y	29.89%
OCF Growth	20.6%
OCF Growth Q	14.14%
OCF Growth10 Y	18.48%
OCF Growth3 Y	60.84%
OCF Growth5 Y	28.75%
Revenue Growth	23.49x
Revenue Growth Q	27.04x
Revenue Growth Quarters	4x
Revenue Growth Years	16x
Revenue Growth3 Y	42.61x
Revenue Growth5 Y	30.29x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.61
Assets	$5.4B
Cash	$629.9M
Current Assets	$2.2B
Current Liabilities	$482.5M
Debt	$115.9M
Debt EBITDA	$0.12
Debt Equity	$0.02
Debt FCF	$0.19
Equity	$4.7B
Liabilities	$707.2M
Long Term Assets	$3.2B
Long Term Liabilities	$224.8M
Net Cash	$683.3M
Net Cash By Market Cap	$6.46
Net Cash Growth	85.45%
Net Debt EBITDA	$-0.72
Net Debt Equity	$-0.14
Net Debt FCF	$-1.12
Tangible Book Value	$2.6B
Tangible Book Value Per Share	$18.96
WACC	9.66

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.56
Inventory Turnover	1.36
Net Working Capital	$1.1B
Quick ratio	2.83
Working Capital	$1.7B
Working Capital Turnover	$2.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.66%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	240.54%
1Y total return	9.01%
200-day SMA	77.85
3Y total return	33.36%
50-day SMA	89.45
50-day SMA vs 200-day SMA	50over200
5Y total return	6.34%
All Time High	101.4
All Time High Change	-23.12%
All Time High Date	2026-01-08
All Time Low	10.26
All Time Low Change	659.75%
All Time Low Date	2012-12-31
ATR	3.5
Beta	1
Beta1y	0.73
Beta2y	0.69
Ch YTD	-10.72
High	85.55
High52	101.4
High52 Date	2026-01-08
High52ch	-23.12%
Low	76.52
Low52	51.79
Low52 Date	2025-08-01
Low52ch	50.51%
Ma50ch	-12.86%
Premarket Change Percent	3.05
Premarket Price	$87.66
Premarket Volume	8,545
Price vs 200-day SMA	0.12%
RSI	27.43
RSI Monthly	52.04
RSI Weekly	43.15
Sharpe ratio	0.34x
Sortino ratio	0.69
Total Return	1.66%
Tr YTD	-10.72
Tr1m	-13.39%
Tr1w	-14.66%
Tr3m	-11.23%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	1
Analyst Price Target Top	$112
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.92
Earnings EPS Estimate Growth	35.29
Earnings Revenue Estimate	738,726,688x
Earnings Revenue Estimate Growth	23.51x
Operating Income	$664M
Operating Income Growth	47.15
Operating Income Growth Q	64.84
Operating Income Growth3 Y	39.36
Operating Income Growth5 Y	36.29
Operating margin	21.41
Price target	$102
Price Target Change	$31.34
Price Target Change Top	$43.68

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	111,637,862%
Float Percent	82.24%
Shares Insiders	17.51%
Shares Institutions	83.63%
Shares Out	135,744,626
Shares Qo Q	1.18%
Shares Yo Y	-1.66%
Short Float	2.97%
Short Ratio	3.13
Short Shares	2.44

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$561.1M
Average Volume	1,324,284.45x
Bv Per Share	34.88
CAPEX	$-168.2M
Ch10y	240.5
Ch1m	-13.39
Ch1w	-14.66
Ch1y	9.01
Ch3m	-11.23
Ch3y	33.36
Ch5y	6.34
Ch6m	-7.08
Change	-8.37%
Change From Open	-8.88
Close	85.07
Days Gap	0.56
Depreciation Amortization	281,074,000
Dollar Volume	470,706,765.4
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$664M
EBITDA	$945.1M
EPS	$4.29
F Score	7
FCF	$610.3M
FCF EV Yield	6.17x
FCF Per Share	$4.5
Financing CF	-25,567,000
Fiscal Year End	December
Founded	2,003
Goodwill	1,438,733,000
Graham Number	58.01986
Graham Upside	-25.57
Income Tax	$71.8M
Investing CF	-669,073,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Lynch Fair Value	$107
Lynch Upside	37.56
Ma150	84.51
Ma150ch	-7.76%
Ma20	91.6
Ma20ch	-14.9%
Net CF	99,684,000
Next Earnings Date	2026-08-06
Open	85.55
Optionable	Yes
P FCF Ratio	17.34
P OCF Ratio	13.59
Position In Range	15.84
Post Close	77.95
Postmarket Change Percent	1.35
Postmarket Price	$79
Ppne	619,343,000
Pre Close	85.07
Price Date	2026-05-08
Price EBITDA	$11.2
Ptbv Ratio	4.11
Relative Volume	4.56x
Revenue	3,100,664,000x
SBC By Revenue	1.59x
Share Based Comp	49,190,000
Tax By Revenue	2.31x
Tax Rate	10.9%
Tr6m	-7.08%
Us State	Pennsylvania
Volume	6,038,573
Z Score	9.96

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GMED pay a dividend?

Capital-return profile for this ticker.

Performance

GMED stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GMED?

Insider, institutional, and short-interest positioning.

Institutional ownership

+83.6%

Float: +82.2% of shares outstanding

Insider ownership

+17.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GMED momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

27.4

Below 30: short-term oversold

Price vs 200-day MA

+0.1%

50/200-day relationship not available

Beta (5Y)

1.00

Moves roughly with the market

Sharpe ratio

0.34

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GMED

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GMED stock rating?

Globus Medical, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GMED analysis?

The full report lives at /stocks/GMED/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GMED?

The latest report frames GMED around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GMED page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.